Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Recent Advances in its Development Pipeline

January 4, 2011

CARLSBAD, Calif., Jan. 4, 2011 /PRNewswire/ — Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:

    What:      Recent Advances in Isis' Development Pipeline

                Thursday, January 06, 2011 at 12:00 p.m. ET /9:00
    When:       a.m. PT

    Where:     www.isispharm.com

                Live on the Internet.  Simply log onto our Web site
    How:        listed above.

    Contacts:  Kristina Lemonidis
               Director, Investor Relations
               (760) 603-2490

               Amy Blackley, Ph.D.
               Assistant Director, Corporate Communications
               (760) 603-2772

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.


Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world’s first antisense drug and has 22 drugs in development. Isis’ drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer. Isis’ partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

SOURCE Isis Pharmaceuticals, Inc.

Source: newswire

comments powered by Disqus